Trial site
Seoul
Seoul, Seoul-teukbyeolsi 02841, South KoreaNot linked to an institution yet
- 11running trials
- 5closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 25 trials
- Phase 2/31 trial
- Status
- Active, not recruiting6 trials
- Completed5 trials
- Recruiting4 trials
- Enrolling by invitation1 trial
Running trials
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944· Phase 3· Sanofi· Source
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009· Phase 3· Sanofi· Source
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931· Phase 3· Sanofi· Source
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· Phase 3· Sanofi· Source
Active, not recruiting
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· Phase 3· Sanofi· Source
Enrolling by invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· Phase 2· Sanofi· Source
Active, not recruiting
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145· Phase 3· Sanofi· Source
Active, not recruiting
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· Phase 3· Sanofi· Source
Active, not recruiting
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· Phase 2· Sanofi· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error